Sequoia China Leads $80M Pre-IPO Round In Chinese Biotech Firm

BrightGene Bio-Medical Technology Co., a Chinese biopharmaceutical company, has received RMB550 million (US$80.06 million) in a pre-IPO round of financing, led by Sequoia China and HighLight Capital, with participation from GF Qianhe Investment, according to a WeChat announcement released today.

China Money Network

Subscribe & Access the Best Data and Intelligence on Chinese Venture Capital and Tech

Register Now

Want to read this important story?

Access thousands of news articles and data posts over the past 9 years!

Already have an account or paid subscription? Log in

Caishen.Co - Primary Data for China Secondary Investment and Stock Markets